Search

Your search keyword '"Gerassimos Tsourouflis"' showing total 2 results
Start Over Author "Gerassimos Tsourouflis" Publication Type Academic Journals
2 results on '"Gerassimos Tsourouflis"'

1. PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?

Author

Theodoros P. Vassilakopoulos, Alexia Piperidou, Zois Mellios, Evgenia Verigou, Eirini Katodritou, Christina Kalpadakis, Sotirios G. Papageorgiou, Chrysovalantou Chatzidimitriou, Vassilios Prassopoulos, Marina P. Siakantaris, Hara Giatra, Dimitrios Karantanis, Nikolaos Papathanasiou, Loukia Ligdi, Anastasia Kopsaftopoulou, Theoni Leonidopoulou, Vasileios Xanthopoulos, Stamatios Karakatsanis, Effimia Vrakidou, Sophia Chatziioannou, Dimitrios Drougkas, Eleftheria Hatzimichael, Gabriella Gainaru, Maria Palassopoulou, Maria Tsirogianni, Maria Kotsopoulou, Gerassimos Tsourouflis, Evangelia Skoura, Catherine Mainta, Evangelos Terpos, Christos Poziopoulos, Theodora Triantafyllou, Panayiotis Zikos, Argyro Koumarianou, Dimitra Liapi, Vassiliki Pappa, Evgenia Verrou, Panayiotis Tsirigotis, Vassiliki Labropoulou, Helen Papadaki, Ioannis Datseris, Argiris Symeonidis, Maria Bouzani, Maria Bakiri, Themis Karmiris, Maria K. Angelopoulou, and Phivi Rondogianni

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Published
2023
Full Text
View/download PDF

2. Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients

Author

Theodoros P. Vassilakopoulos, Maria Arapaki, Panagiotis T. Diamantopoulos, Athanasios Liaskas, Fotios Panitsas, Marina P. Siakantaris, Maria Dimou, Styliani I. Kokoris, Sotirios Sachanas, Marina Belia, Chrysovalantou Chatzidimitriou, Elianna A. Konstantinou, John V. Asimakopoulos, Kyriaki Petevi, George Boutsikas, Alexandros Kanellopoulos, Alexia Piperidou, Maria-Ekaterini Lefaki, Angeliki Georgopoulou, Anastasia Kopsaftopoulou, Kalliopi Zerzi, Ioannis Drandakis, Maria N. Dimopoulou, Marie-Christine Kyrtsonis, Panayiotis Tsaftaridis, Eleni Plata, Eleni Variamis, Gerassimos Tsourouflis, Flora N. Kontopidou, Kostas Konstantopoulos, Gerassimos A. Pangalis, Panayiotis Panayiotidis, and Maria K. Angelopoulou

Subjects
Hodgkin’s lymphoma, β2-microglobulin, prognostic factors, chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

The significance of serum beta-2 microglobulin (sβ2m) in Hodgkin lymphoma (HL) is controversial. We analyzed 915 patients with HL, who were treated with ABVD or equivalent regimens with or without radiotherapy. Sβ2m levels were measured by a radioimmunoassay (upper normal limit 2.4 mg/L). Sequential cutoffs (1.8–3.0 by 0.1 mg/L increments, 3.5 and 4.0 mg/L) were tested along with ROC analysis. The median sβ2m levels were 2.20 mg/L and were elevated (>2.4 mg/L) in 383/915 patients (41.9%). Higher sβ2m was associated with inferior freedom from progression (FFP) at all tested cutoffs. The best cutoff was 2.0 mg/L (10-year FFP 83% vs. 70%, p = 0.001), which performed better than the 2.4 mg/L cutoff (“normal versus high”). In multivariate analysis, sβ2m > 2.0 mg/L was an independent adverse prognostic factor in the whole patient population. In multivariate overall survival analysis, sβ2m levels were predictive at 2.0 mg/L cutoff in the whole patient population and in advanced stages. Similarly, sβ2m > 2.0 mg/L independently predicted inferior HL-specific survival in the whole patient population. Our data suggest that higher sβ2m is an independent predictor of outcome in HL but the optimal cutoff lies within the normal limits (i.e., at 2.0 mg/L) in this predominantly young patient population, performing much better than a “normal versus high” cutoff set at 2.4 mg/L.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results